NGNE

NASDAQ 已收盘

Neurogene

22.93 USD
▼-0.21-0.91%
盘后 23.26 +1.44%
2026-11-19
市值
$458.53M
市盈率
—
EPS
-5.03
股息率
—
52 周区间
15.93 – 43.66
成交量
151.34K
Beta
2.10
目标价
77.63
52W 低 15.9352W 高 43.66
价格走势

公司简介

Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The comp...